Navigation Links
Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
Date:2/22/2010

ogram, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application submission in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF), to develop and commercialize AZ-004 in the U.S. and Canada.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose).  Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
2. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
3. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
4. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
6. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
7. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
8. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
9. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
10. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
11. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... News) -- People with higher levels of brown fat ... new study suggests. Unlike white fat, which lowers ... insulin sensitivity, blood sugar control and fat-burning metabolism. ... Labros Sidossis, a professor of internal medicine in the ... Medical Branch at Galveston, said in a university ...
(Date:7/28/2014)... decision tree analysis, incorporating Donabedian,s model, is a ... available quality standards, guidelines, recommendations and indicators ... standards for radiation therapy, according to a study ... Practical Radiation Oncology (PRO), the official clinical ... Oncology (ASTRO). , Guidelines, recommendations and indicators may ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
Breaking Medicine News(10 mins):Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2
... find themselves in a sticky situation having failed to meet ... lapses in// sticking to rules pertaining to blood safety, ... the total penalty toll against the American Red Cross ... the organization had been fined close to $5.7 million, ...
... amyotrophic lateral sclerosis (ALS), the most common form of ... successful compiling of genetic information on more than 1,000 ... by The Packard Center for ALS Research at Johns ... (NINDS) and the ALS Association, present their initial findings ...
... a lot of other countries, Japan is keen to ... universities, which are currently restricted only to those// who ... of the undergraduate courses like biotechnology and neurosciences to ... prime minister. He is also a professor at the ...
... to the needs of about 1,000 people annually. ... Award for Excellence in Weight// Management 2006 to ... standards that were maintained by this clinic. Glowing ... that offer simple,yet comprehensive solutions to treat obesity. ...
... South Africans are coming forward to seek counseling and ... HIV figures, the Department of Health has reported.// ... have utilized the screening services since 2000, thanks to ... their status. In 2005/06, nearly 1.7-million people underwent the ...
... Welfare stressed the urgency to focus on health and education. ... million people are suffering with HIV/AIDS, and also putting a ... be noted that more than 50 percent of the AIDS ... to be women. Ramadoss expressed how the campaign had slightly ...
Cached Medicine News:Health News:American Red Cross Face Fines After Blood Safety Lapses 2Health News:First International Gene Screen for Typical ALS Is on Track 2
Double Ended Occluders...
49 pinholes, black...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: